AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comNOV 42 min read$AMGN

Amgen lifts 2026 outlook as Repatha and Imdelltra offset biosimilar hit to Prolia

Amgen reported Q3 2026 revenue of $10.37B, up 8% YoY, beating estimates. Non-GAAP EPS rose 14% to $6.45, while GAAP EPS increased 19% to $7.08. The company attributed growth to Repatha and Imdelltra, offsetting a biosimilar impact on Prolia.

Original reporting
thepharmaletter.com
Published Nov 4, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen lifts 2026 outlook as Repatha and Imdelltra offset biosimilar hit to Prolia — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The earnings beat and guidance raise suggest near-term upside for AMGN.

02

Market read

Amgen's earnings beat is a primary catalyst for its stock and may influence the biotech sector.

03

What to watch

Potential headwinds from biosimilar competition on Prolia could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Amgen's Q3 2026 earnings were released, showing revenue growth and EPS beat.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported Q3 2026 revenue of $10.37B and EPS beat expectations, lifting its 2026 outlook.

Expected impact

upward pressure as market prices in the earnings beat and outlook lift

Evidence & confidence

The company posted better-than-expected revenue and EPS, and raised its 2026 guidance, which typically triggers buying interest.

Market effects

Sector

Biotech sector may see modest rally on Amgen's strong performance.

Regional

U.S. biotech stocks could benefit from the earnings beat.

Global

Limited to investors tracking large-cap pharma earnings.

Counterpoint

What could challenge this read

If the outlook lift is already priced in, the stock may face a pullback.

Key entities

  • company
    Amgen

    U.S. biotech major reporting Q3 2026 earnings.

Read at source← All news

StoryAmgen posts Q3 2026 earnings beat and lifts 2026 revenue and EPS outlook

Also covered by

6 outlets

Related articles

NOV 4
$AMGNLow

Amgen starts MariTide autoinjector study as pivotal readouts approach

Amgen (AMGN) is advancing its GLP-1 drug candidate, MariTide, with a new Phase 3 study for autoinjector use, aiming for a 2027 completion. The company expects pivotal Phase 3 data next year, with dosing frequency and tolerability as key focus areas. Amgen plans $2.6B in capital expenditures this year, partly for MariTide manufacturing. Q3 revenues rose 8% to $10.4B, with strong performance from key brands.

biospace.com1 min
NOV 4
$AMGNMed

Amgen stock price target raised to $531 by TD Cowen on growth

TD Cowen raised its price target on Amgen (AMGN) to $531 from $452, citing strong Q3 2026 results and growth prospects. The stock trades near its 52-week high. Amgen's revenue and EPS guidance were increased, driven by products like Uplizna and Imdelltra. Multiple analysts revised earnings upwards, though the stock is slightly overvalued according to InvestingPro.

investing.com2 min
NOV 4
$AMGNMedAI 8/10

Truist raises Amgen stock price target on earnings beat

Truist Securities raised its price target for Amgen (AMGN) to $398 from $380, maintaining a Hold rating. The stock is near its 52-week high after Q3 2026 earnings beat expectations, with revenue of $10.4B and EPS of $6.45. Amgen raised full-year revenue and EPS guidance. Analysts cite strong performance and pipeline potential as key drivers.

investing.com2 min